Mike Mussallem, CEO of Edwards Lifesciences (NYSE: EW)
outliers.substack.com
A share of Edwards Lifesciences, a medical technology company, delivered 7,670% return since the start of trading on the top of dotcom bubble in March 2000. S&P 500 returned 153% for the same period. Over the past 20 years CEO Mike Mussallem turned an obscure company, which was the worst performing business unit of Baxter at the time, into a global medtech leader focused on cardiovascular products and services. The magnitude of value created by Mussallem is astonishing - at the time when it was a part of Baxter, Edwards was valued at $230m. Today Edwards has market cap of $55B.
Mike Mussallem, CEO of Edwards Lifesciences (NYSE: EW)
Mike Mussallem, CEO of Edwards Lifesciences…
Mike Mussallem, CEO of Edwards Lifesciences (NYSE: EW)
A share of Edwards Lifesciences, a medical technology company, delivered 7,670% return since the start of trading on the top of dotcom bubble in March 2000. S&P 500 returned 153% for the same period. Over the past 20 years CEO Mike Mussallem turned an obscure company, which was the worst performing business unit of Baxter at the time, into a global medtech leader focused on cardiovascular products and services. The magnitude of value created by Mussallem is astonishing - at the time when it was a part of Baxter, Edwards was valued at $230m. Today Edwards has market cap of $55B.